TULVEGIO RIVOCERANIB
Live / Allowed — Second extension granted (statement of use) (as of 25 Aug 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 13 Aug 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98695795
- Mark type
- Design + words
- Filed
- 13 Aug 2024
- Published for opposition
- 08 Jul 2025
- Attorney of record
- Cynthia Johnson Walden
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances containing rivoceranib for the treatment of cancer
- Class 042 — Scientific and technological services: Development of therapeutics in the nature of pharmaceutical preparations for the treatment of cancer containing rivoceranib
Owner
- Elevar Therapeutics, Inc., Fort Lee, NJ, US
- Elevar Therapeutics, Inc., Salt Lake City, UT, US
Prosecution history
- 25 Aug 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Aug 2026 — SOU EXTENSION 2 GRANTED
- 25 Aug 2026 — SOU EXTENSION 2 FILED
- 25 Aug 2026 — SOU TEAS EXTENSION RECEIVED
- 14 May 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Feb 2026 — SOU EXTENSION 1 GRANTED
- 09 Feb 2026 — SOU EXTENSION 1 FILED
- 09 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 02 Sept 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 08 Jul 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 08 Jul 2025 — PUBLISHED FOR OPPOSITION
- 02 Jul 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 02 Jun 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 08 May 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 08 May 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE